HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Eivind Øvrum Leif Nilsson Jan W. Borowiec Stefan Thelin Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Øvrum, E. Articles by Thelin, S. Search for Related Content PubMed PubMed Citation Articles by Øvrum, E. Articles by Thelin, S.

Ann Thorac Surg 1996;61:1038-1039
© 1996 The Society of Thoracic Surgeons

---

Correspondence

Eosinophil Granulocyte Activation and Heparin-Coated Cardiopulmonary Bypass

Oslo Heart Center Pilestredet 32 0027 Oslo Norway

The first 20% of the full text of this article appears below.

To the Editor:

I read with great interest the recent article entitled ``Eosinophil granule proteins in cardiopulmonary bypass with and without heparin coating'' by Nilsson and associates [1]. They studied activation of eosinophil granulocytes expressed by release of eosinophil cationic protein and eosinophil protein X in patients undergoing cardiopulmonary bypass with either a Carmeda Bio-Active Surface (Carmeda, Stockholm, Sweden) coated system or ordinary uncoated equipment. The systemic heparin doses were reduced to 50% and 75% of normal doses in two heparin-coated groups. They demonstrated significantly less release of the eosinophil proteins in the patients treated with heparin-coated cardiopulmonary bypass, which was interpreted as evidence of improved biocompatibility of the heparin-coated circuit. However, like in several other reports on heparinized CPB [2--4], their study design implicated changing of two parameters at the same time, namely, the presence of heparin-coated surfaces and reducing the amount of systemic heparin. Therefore, their conclusion may be questioned, as the influence of lowering the level of circulating heparin remained unknown.

My colleagues and I have made a similar study on neutrophil activation [5], investigating the effects of both the concentration of circulating heparin and the surface-bound heparin by including three groups of patients: two groups have heparin-coated (Duraflo II; Baxter-Bentley Laboratories, Irvine, CA) cardiopulmonary bypass, one group given low-dose . . . [Full Text of this Article]

Leif Nilsson, MDPhD, Per Venge, MDPhD, Jan W. Borowiec, MDPhD, Stefan Thelin, MDPhD

Departments of Thoracic Surgery Clinical Chemistry University Hospital S-751 85 Uppsala Sweden

This article has been cited by other articles:

				C B. Mahoney Heparin-bonded circuits: clinical outcomes and costs Perfusion, May 1, 1998; 13(3): 192 - 204. [Abstract] [PDF]

				F. Bizzarri, E. Carone, G. Capannini, G. Davoli, G. Lisi, M. Maccherini, G. Sani, and M. Toscano Bleeding reduction in cardiac surgery: A combined approach J. Thorac. Cardiovasc. Surg., May 1, 1998; 115(5): 1227 - 1227. [Full Text] [PDF]

				E. Ovrum, E. A. Holen, G. Tangen, and M.-A. L. Ringdal Heparinized Cardiopulmonary Bypass and Full Heparin Dose Marginally Improve Clinical Performance Ann. Thorac. Surg., October 1, 1996; 62(4): 1128 - 1133. [Abstract] [Full Text]